A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer.

Trial Profile

A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs Lonafarnib (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 28 Jul 2009 Actual initiation date changed from Dec 2003 to Sep 2004 as reported by ClinicalTrials.gov.
    • 28 Jul 2009 Actual initiation date changed from Dec 2003 to Sep 2004 as reported by ClinicalTrials.gov.
    • 22 Dec 2008 Planned end date changed from 1 Dec 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top